ECSP18006465A - Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h - Google Patents

Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h

Info

Publication number
ECSP18006465A
ECSP18006465A ECIEPI20186465A ECPI201806465A ECSP18006465A EC SP18006465 A ECSP18006465 A EC SP18006465A EC IEPI20186465 A ECIEPI20186465 A EC IEPI20186465A EC PI201806465 A ECPI201806465 A EC PI201806465A EC SP18006465 A ECSP18006465 A EC SP18006465A
Authority
EC
Ecuador
Prior art keywords
inhibitor
isocitrate dehydrogenase
adduct
idh1
mutated isocitrate
Prior art date
Application number
ECIEPI20186465A
Other languages
English (en)
Inventor
Heiko Schirmer
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of ECSP18006465A publication Critical patent/ECSP18006465A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al ácido aductivo (2E)-but-2-enedioico y ácido 3-(2-{[4-(trifluorometoxi)fenil]amino}-1-[(1R,5R)-3,3,5-trimetilciclohexil]-1H-benzimidazol-5-il)propanoico (1:4), a métodos para preparar este aducto, composiciones que comprenden este aducto y, también al uso de este aducto para preparar un medicamento para el tratamiento de una enfermedad.
ECIEPI20186465A 2015-07-27 2018-01-26 Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h ECSP18006465A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15178419 2015-07-27

Publications (1)

Publication Number Publication Date
ECSP18006465A true ECSP18006465A (es) 2018-04-30

Family

ID=53758092

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI20186465A ECSP18006465A (es) 2015-07-27 2018-01-26 Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h

Country Status (26)

Country Link
US (1) US10344004B2 (es)
EP (1) EP3328837B1 (es)
JP (1) JP6804516B2 (es)
KR (1) KR20180030789A (es)
CN (1) CN107810181B (es)
AR (1) AR105493A1 (es)
AU (1) AU2016300980B2 (es)
BR (1) BR112018001534A2 (es)
CA (1) CA2993473A1 (es)
CL (1) CL2018000249A1 (es)
CO (1) CO2018000793A2 (es)
CR (1) CR20180053A (es)
CU (1) CU20180014A7 (es)
DO (1) DOP2018000027A (es)
EA (1) EA201890386A1 (es)
EC (1) ECSP18006465A (es)
ES (1) ES2860693T3 (es)
HK (1) HK1252449A1 (es)
IL (1) IL256024A (es)
MX (1) MX2018001205A (es)
NI (1) NI201800014A (es)
PE (1) PE20181038A1 (es)
SV (1) SV2018005621A (es)
TN (1) TN2018000038A1 (es)
TW (1) TW201708193A (es)
WO (1) WO2017016992A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2732902T3 (es) 2014-02-11 2019-11-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Bencimidazol-2-aminas como inhibidores de MIDH1
PE20170143A1 (es) 2014-02-11 2017-03-19 Bayer Pharma AG Benzimidazol-2-aminas como inhibidores de midh1
ES2814151T3 (es) 2014-10-23 2021-03-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts 1-Ciclohexilo-2-fenilaminobenzimidazoles como inhibidores de MIDH1 para el tratamiento de tumores
WO2016198322A1 (en) 2015-06-08 2016-12-15 Bayer Pharma Aktiengesellschaft N-menthylbenzimidazoles as midh1 inhibitors
CN107949557B (zh) 2015-07-07 2021-11-02 德国癌症研究公共权益基金会 作为mIDH1抑制剂的2-芳基-和2-芳烷基-苯并咪唑类
US10414734B2 (en) 2015-07-16 2019-09-17 Bayer Pharma Aktiengesellschaft 5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors
EP3121166A1 (en) 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201718513A (zh) 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法
WO2019015672A1 (zh) * 2017-07-21 2019-01-24 南京明德新药研发股份有限公司 吡啶并咪唑类化合物及其应用
WO2019025256A1 (en) 2017-08-01 2019-02-07 Bayer Aktiengesellschaft COMBINATION OF MIDH1 INHIBITORS AND DNA HYPOMETHYLATION (AHM) AGENTS
CN108948205B (zh) * 2018-07-13 2021-09-28 北京金岱生物科技有限公司 抗idh1r132h单克隆抗体及其应用
TWI760017B (zh) * 2019-12-23 2022-04-01 大陸商昆藥集團股份有限公司 一種ｉｄｈ１突變體抑制劑的鹽型、晶型及其製備方法
EP4186525A4 (en) 2020-07-21 2024-04-03 Daiichi Sankyo Company, Limited COMBINATION DRUG OF TEMOZOLOMIDE AND MUTATED IDH1 ENZYME INHIBITOR

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2766550C (en) * 2009-06-23 2017-04-11 The Translational Genomics Research Intstitute Benzamide derivatives
CN103476770B (zh) * 2010-11-25 2017-02-15 拉蒂欧制药有限责任公司 阿法替尼盐和多晶型物
MX342326B (es) * 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
PE20170143A1 (es) 2014-02-11 2017-03-19 Bayer Pharma AG Benzimidazol-2-aminas como inhibidores de midh1
ES2732902T3 (es) * 2014-02-11 2019-11-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts Bencimidazol-2-aminas como inhibidores de MIDH1
ES2814151T3 (es) 2014-10-23 2021-03-26 Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts 1-Ciclohexilo-2-fenilaminobenzimidazoles como inhibidores de MIDH1 para el tratamiento de tumores
US10138226B2 (en) * 2014-10-23 2018-11-27 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as MIDH1 inhibitors
WO2016198322A1 (en) 2015-06-08 2016-12-15 Bayer Pharma Aktiengesellschaft N-menthylbenzimidazoles as midh1 inhibitors
CN107949557B (zh) 2015-07-07 2021-11-02 德国癌症研究公共权益基金会 作为mIDH1抑制剂的2-芳基-和2-芳烷基-苯并咪唑类
US10414734B2 (en) * 2015-07-16 2019-09-17 Bayer Pharma Aktiengesellschaft 5-hydroxyalkylbenzimidazoles as mIDH1 inhibitors
EP3121166A1 (en) * 2015-07-21 2017-01-25 Bayer Pharma Aktiengesellschaft Fused imidazoles as midh1 inhibitors
TW201718513A (zh) * 2015-07-27 2017-06-01 拜耳製藥公司 製備經取代之３－（２－苯胺－１－環己基－１ｈ－苯并咪唑－５－基）丙酸衍生物之方法

Also Published As

Publication number Publication date
MX2018001205A (es) 2018-04-24
CO2018000793A2 (es) 2018-05-10
CN107810181A (zh) 2018-03-16
EP3328837A1 (en) 2018-06-06
AU2016300980A1 (en) 2017-12-21
US10344004B2 (en) 2019-07-09
TN2018000038A1 (en) 2019-07-08
TW201708193A (zh) 2017-03-01
SV2018005621A (es) 2018-12-05
CN107810181B (zh) 2021-06-22
JP6804516B2 (ja) 2020-12-23
CL2018000249A1 (es) 2018-07-06
CU20180014A7 (es) 2018-06-05
HK1252449A1 (zh) 2019-05-24
PE20181038A1 (es) 2018-07-03
NI201800014A (es) 2018-09-06
KR20180030789A (ko) 2018-03-26
ES2860693T3 (es) 2021-10-05
WO2017016992A1 (en) 2017-02-02
AU2016300980B2 (en) 2020-12-24
EP3328837B1 (en) 2021-01-06
US20180222870A1 (en) 2018-08-09
BR112018001534A2 (pt) 2018-09-11
CR20180053A (es) 2018-03-20
AR105493A1 (es) 2017-10-11
DOP2018000027A (es) 2018-02-28
JP2018521095A (ja) 2018-08-02
EA201890386A1 (ru) 2018-08-31
IL256024A (en) 2018-01-31
CA2993473A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
ECSP18006465A (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
CO2018006299A2 (es) Compuestos novedosos
CL2019001066A1 (es) Sal de (s)-csa de s-ketamina, sal de (r)-csa de s-ketamina y procesos para la preparación de s-ketamina (divisional solicitud 201702854)
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
EA201790398A1 (ru) Способы лечения заболевания печени
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CR20170242A (es) Benzamidas sustituidas copn 1,3-tiazol-2-ilo
EA201691134A1 (ru) Новые ингибиторы глутаминазы
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
UY35933A (es) Composiciones farmacéuticas que comprenden azd9291
CO2018000795A2 (es) Método para preparar derivados de ácido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido
CR20170425A (es) Nuevas proteínas específicas para pioverdina y pioquelina
DOP2016000253A (es) Nuevos compuestos
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
BR112013030554A2 (pt) forma cristalina de ciclosporina a, métodos de preparação e métodos para uso da mesma
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
MX2017002610A (es) INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
CO7131387A2 (es) Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido
EA201691792A1 (ru) Фармацевтические составы на основе вилдаглиптина
EA201691498A1 (ru) Новая мишень для лечения и профилактики диабета
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
BR112017024126B8 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos